Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

June 2020

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders

– Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, 3 and 5 were approved at the Annual Meeting – Scheduled to Reconvene July 23, 2020, 9:00 am Eastern Daylight Time Jun 29, 2020, 07:30 ET CRANBURY, N.J., June 29, 2020 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) …

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders Read More »

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications

– Engages with Scientific, Governmental and Regulatory Agencies – Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial Jun 23, 2020, 07:30 ET CRANBURY, N.J., June 23, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide …

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications Read More »

Scroll to Top